Teva converts Copaxone users
Generic Copaxone may not gut Teva's earnings if the drugmaker continues to convert users to its latest formulation. “'We may have failed to understand just how comprehensive Teva's patient outreach system has been,” Cowen analyst Ken Cacciatore tells Bloomberg Businessweek.
Businessweek reports that Teva has managed to migrate 8.7% of its 20mg prescriptions to the new, three-times-a week 40mg version of the MS drug as of February 28.
Teva anticipated that generic Copaxone could inflict serious damage on its outlook, so much so that its 2014 guidance included life-with and life-without generic Copaxone numbers.
Teva said in December that every month without generic Copaxone enriches it by $78 million. Bloomberg reported at the time that the generic could push Teva into its first sales drop in two decades.